Innovation in Life Sciences
Thursday 25 September 2008 09:30 to 17:45
Location
Clifford Chance, 10 Upper Bank Street, Canary Wharf, London E14 5JJParticipants

Confirmed Speakers and Panelists include:
- Roy Alder, past Director of Policy at the Medicines and Healthcare products (sic) Agency
- Fabienne Bartoli, Deputy Director General, Agence française de sécurité sanitaire des produits de santé (Afssaps)
- Andrew Baum, Pharma Research Team, Morgan Stanley
- David Body, Irwin Mitchell
- Professor Sir Alasdair Breckenridge, CBE, Chairman, MHRA
- Jeffrey Bucholtz, Department of Justice, USA
- Alex Denoon, Clifford Chance
- Dr Peter Feldschreiber, MHRA, 4 New Square
- Sara Gourley, Sidley Austin LLP
- Joseph Hetrick, Dechert
- Dr Duncan Fairgrieve, British Institute of International and Comparative Law, 1 Crown Office Row
- The Hon. Mr Justice Jackson
- James Lawford - Davies, Clifford Chance
- Professor Chris Mason, University College London
- Dr Alexandra McConnell, Clifford Chance
- Professor Mark Mildred, Nottingham Law School, Nottingham Trent University
- Leigh-Ann Mulcahy, 4 New Square
- Professor Munir Pirmohamed, NHS Chair of Pharmacogenetics, Department of Pharmacology, University of Liverpool
- Nathalie Rampal Olmedo, European Medicines Agency
- Alexandre Regniault, Simmons & Simmons
- Helen Usmar, Director EMEA, Deputy EU Qualified Person for Pharmacovigilance, Stiefel Laboratories
- Professor Kent Woods, CEO, MHRA.
Further speakers from science, legal academia, industry, French Medicines Regulator and UK House of Commons are to be confimed.


Topics:
- Innovation in Science: What Innovative Research is and how it is Produced - the View from the Lab Bench
- The Regulatory Response to Innovation: Policy Issues for Innovation Compared to Traditional Drugs
- Industry and Innovation: Challenges for Industry
- Using the Advanced Therapies Regulations to Facilitate Innovation
- IP Challenges and Issues with Innovative Products and Therapies - Stem Cells Example
- EU/US Comparison of Institutional Shifts in Regulators Necessary to Regulate Global Innovation and Lessons from Off-Label Use
- The Precautionary Principle: its centrality and (mis)-Application in Regulatory Decision-Daking
- Product Liability: Challenges to Innovation by Civil Liability Claims
- Regulation and Liability Interplay: US Pre-emption Case Law and European Comparative Analysis
- Socio-Political Implications: Future Policy-Making and Public Consultations
17.45 to 19.15 - Book Launch of OUP Book, The Law and Regulation of Medicines, edited by Dr Peter Feldschreiber.
This event will be followed by a dinner at The Travellers Club with the speakers and will cost £80 per person.
Please click here for a copy of the programme
This event is kindly sponsored by





.jpg)
.gif)



Moore Wilson -